NCT01965119

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is that ruxolitinib may be a possible treatment option for relapsed or refractory patients with Hodgkin and primary mediastinal large B-cell lymphoma.

Detailed description

Patients will take ruxolitinib 20 mg orally twice a day, 40mg in total per day, for 4 weeks.4 weeks is 1 cycle. Treatment will be continued until documented disease progression or unacceptable toxicity and the maximum period of treatment is 16 cycles.

Conditions

• Relapsed or Refractory Hodgkin Lymphoma
• Primary Mediastinal Large B-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Ruxolitinib	20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.

Timeline

• Start date: 2013-11-15
• Primary completion: 2017-06-30
• Completion: 2018-09-18
• First posted: 2013-10-18
• Last updated: 2018-11-01

Locations

7 sites across 1 country: South Korea